Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
AGE ANAEMIA study of postoperative intravenous ferric derisomaltose after cardiac surgery
NL-OMON59266Phase 4Recruiting
- Sponsor
- St. Antonius Ziekenhuis
- Start
- Aug 2024
- Modality
- Small Molecules, Biodegradable Polymers → Polymer-based Nanoparticles → Nanoparticles → Drug Delivery Systems
- Countries
- 1
01
Overview
Phase 4, randomised trial of ferric derisomaltose in iron deficiency anemia (IDA) (2 arms), sponsored by St. Antonius Ziekenhuis. Primary endpoint: Disability at postoperative day 90. Started Aug 2024; status: recruiting.
02
Drugs
ferric derisomaltose
03
Conditions
iron deficiency anemia (IDA)
Beyond the preview
Go deeper on NL-OMON59266.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON59266.